| Previous close | 0.900 |
| Open | 0.900 |
| Bid | 0.840 x 0 |
| Ask | 0.860 x 0 |
| Day's range | 0.820 - 0.900 |
| 52-week range | 0.820 - 2.300 |
| Volume | |
| Avg. volume | 825,448 |
| Market cap | 870.974M |
| Beta (5Y monthly) | 0.63 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.140 |
| Earnings date | 25 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.98 |
PR NewswireGannex Announces Poster Presentation of Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy-Confirmed MASH at EASL CONGRESS 2024
Gannex Pharma Co., Ltd. ("Gannex"), a wholly-owned company of Ascletis Pharma Inc. (HKEX:1672, "Ascletis") dedicated to the research and development and commercialization of new drugs in the field of metabolic dysfunction-associated steatohepatitis (MASH), today announced a poster presentation at the European Association for the Study of the Liver (EASL) Congress 2024, held June 5-8, 2024 in Milan, Italy. A copy of the poster is available under the Posters/Publications page of Gannex's website a
PR NewswireAscletis Announces Strategic Decisions on FXR agonist ASC42
Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces today the strategic decisions on farnesoid X receptor (FXR) agonist ASC42.
PR NewswireAscletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces the poster presentation of Phase II study final results of ASC40, a first-in-class fatty acid synthase (FASN) inhibitor for treatment of acne, at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, the United States.
